tiprankstipranks
Advertisement
Advertisement
Orthocell Issues Cautious Q4 FY26 Investor Presentation Disclaimer
PremiumCompany AnnouncementsOrthocell Issues Cautious Q4 FY26 Investor Presentation Disclaimer
2M ago
Orthocell hits record revenue as Remplir adoption accelerates and global rollout advances
Premium
Company Announcements
Orthocell hits record revenue as Remplir adoption accelerates and global rollout advances
2M ago
Orthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir
Premium
Company Announcements
Orthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir
2M ago
Orthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study
PremiumCompany AnnouncementsOrthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study
4M ago
Orthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing
Premium
Company Announcements
Orthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing
5M ago
Orthocell records first U.S. military hospital case for Remplir after DoD–VA approval
Premium
Company Announcements
Orthocell records first U.S. military hospital case for Remplir after DoD–VA approval
5M ago
Orthocell reports lapse of 16,567 retention rights, trimming potential equity
PremiumCompany AnnouncementsOrthocell reports lapse of 16,567 retention rights, trimming potential equity
6M ago
Orthocell Issues New Retention and Performance Rights Under Employee Incentive Plan
Premium
Company Announcements
Orthocell Issues New Retention and Performance Rights Under Employee Incentive Plan
6M ago
Orthocell Taps LEDA for UK Launch of Remplir Nerve Repair Device
Premium
Company Announcements
Orthocell Taps LEDA for UK Launch of Remplir Nerve Repair Device
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100